Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Nvidia Options Price in $280 Billion Earnings Swing 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Trump Buys SpaceX Shares After Record IPO 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
California Seeks Paramount Divestitures in Warner Bros. Merger 
 and Lead Plaintiff Deadline - May 28, 2018 - EconoTimes)
Add as a preferred source on Google
NEW YORK, May 02, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sldb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Solid’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) The company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sldb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Solid you have until May 28, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
